KOENIG DAVID 4

4 · ProUroCare Medical Inc. · Filed Mar 19, 2012

Form 4

Period: 2012-03-16

Director

Transactions

Award
Common stock, $0.00001 par value
2012-03-16$1.00/sh+19,000$19,000→ 181,824 total

Holdings

Warrants
Exercise: $1.30Exp: 2013-08-02→ Common stock, $0.00001 par value (50,000 underlying)
50,000
Stock options
Exercise: $0.87Exp: 2018-08-09→ Common stock, $0.00001 par value (28,736 underlying)
28,736
Convertible Note
Exercise: $1.10Exp: 2012-02-28→ Common stock, $0.00001 par value
Common Stock, $0.00001 par value
(indirect: Shares held by Clinical Network Management Corp., of which reporting person is a managing officer.)
1,875
Stock Options
Exercise: $1.72Exp: 2017-08-10→ Common stock, $0.00001 par value (14,535 underlying)
14,535
Stock Options
Exercise: $11.33Exp: 2012-04-19→ Common Stock, $0.00001 par value (3,000 underlying)
3,000
Stock options
Exercise: $1.50Exp: 2016-09-29→ Common stock, $0.00001 par value (50,000 underlying)
50,000
Common Stock, $0.00001 par value
(indirect: Shares held by Clinical Network Inc., of which the reporting person is a managing officer.)
26,571

Footnotes (5)

[F1]Currently exercisable.
[F2]Options shall vest on the latter of the date that the Company is cleared by the FDA to sell the ProUroScan System in the United States or the date the Company closes on an aggregate of $2,000,000 or more of incremental equity financing after the date of grant(including the exercise of existing warrants).
[F3]Annual option award pursuant to the Issuer's compensation policy for Directors upon their re-election to the Board of Directors at its annual shareholders' meeting on August 9, 2011. The seven-year options vest ratably over 12 months.
[F4]On December 1, 2011, the reporting person and the Company executed a convertible promissory note in the principal amount of $6,400 with a maturity date of February 28, 2012. The principal amount and interest accruing at a rate of 10% per year are convertible into common shares at $1.10 per share at any time through the maturity date. The number of shares to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within 2 business days after conversion. The issuer's Board of Directors specifically approved the transaction as exempt from the requirements of Section 16b as provided by Rules 16b-3(d).
[F5]Shares issued in lieu of cash for consulting fees as approved by the Board of Directors which are exempt under section 16b-3(d).

Documents

1 file